ArticleIJU case reports2026
Incidentally Detected Ductal Adenocarcinoma Presenting With Isolated Pulmonary Metastasis and a BRCA2 Mutation.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incidentally Detected Ductal Adenocarcinoma Presenting With Isolated Pulmonary Metastasis and a BRCA2 Mutation.IJU case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ductal adenocarcinoma of the prostate is a rare and aggressive cancer that often presents with low prostate-specific antigen levels and nonspecific urinary symptoms, leading to a delayed diagnosis. Mutations in DNA repair genes such as BRCA2 may render these cancers susceptible to targeted treatments. Case Presentation: A 78-year-old man developed acute urinary retention despite a prostate-specific antigen of 0.731 ng/mL. Histopathological examination after holmium laser enucleation of the prostate revealed a ductal adenocarcinoma. Imaging revealed multiple lung nodules, and partial lung resection confirmed metastasis. Genomic profiling of the lung metastases revealed a pathogenic BRCA2 mutation. The patient received androgen deprivation therapy, followed by a combination of talazoparib and enzalutamide. Six months later, imaging revealed fewer lung metastases. Conclusion: This case illustrates the diagnostic challenges of low-prostate-specific antigen ductal adenocarcinoma and demonstrates the potential of molecular profiling to guide personalized treatment with targeted therapies for rare prostate cancer subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.